Rosenwald J C, Bridier A, Sabattier R, Guillot R, Louis M, Schlienger P, Habrand J L, Desjardins L, Haye C, Bloch-Michel E
Institut Curie, Section Médicale et Hospitalière, Paris.
Ophtalmologie. 1990 Jan-Feb;4(1):123-7.
Using proton beams for treatment of malignant tumors of the eye allows high dose irradiation of the tumor volume with negligible irradiation of the surrounding critical structures. Actually, the clinical results reported from the Boston or Villigen groups which have experience of such a technique, are impressive. In France, it is planned to use soon 200 MeV proton beams from the Orsay synchrocyclotron 20 km from Paris. Therefore, a feasibility study has been conducted during year 1988, consisting of a dosimetric analysis of the characteristics of the Orsay proton beams. It was concluded that only simple modifications were necessary to make the beam clinically available for protontherapy and more specifically for treatment of uveal melanomas.
使用质子束治疗眼部恶性肿瘤能够在对周围关键结构照射可忽略不计的情况下，对肿瘤体积进行高剂量照射。实际上，有这种技术经验的波士顿或维利根研究小组所报告的临床结果令人印象深刻。在法国，计划不久后使用距离巴黎20公里的奥赛同步回旋加速器产生的200兆电子伏质子束。因此，在1988年进行了一项可行性研究，包括对奥赛质子束特性的剂量分析。得出的结论是，只需进行简单修改，就可使该束流在临床上用于质子治疗，更具体地用于治疗葡萄膜黑色素瘤。
